AAV-mediated gene therapy as a strategy to fight obesity and metabolic diseases

Carlos Henrique Sponton\textsuperscript{1,2,3} & Shingo Kajimura\textsuperscript{1,2,3} \textsuperscript{a}

The fibroblast growth factor 21 (FGF21) is a member of the FGF superfamily that now comprises 22 members identified in humans. Unlike the canonical role of most FGF family members, FGF21 is released into the circulation and acts as an endocrine hormone by binding with low affinity to FGF receptors (FGFRs) as well as to the co-receptor β-klotho in the target cells to trigger the ERK1/2 and MAPKs signaling pathways. Described initially as a hepatokine, subsequent studies identified significant amounts of FGF21 transcript in the pancreas, the adipose tissue, and the skeletal muscle. FGF21 expression is highly regulated by environmental stimuli such as starvation, ketogenic diet, cold exposure, and exercise.

EMBO Mol Med (2018) 10: e9431
See also: Jimenez et al (August 2018)

Our understanding of the physiological role of FGF21 and its pharmacological effects has expanded substantially over the last decade (Degirolamo et al, 2016). FGF21 exerts a multitude of metabolic benefits, including enhanced liver fatty acid oxidation, inhibition of gluconeogenesis, increased adipose thermogenesis, decreased inflammation in pancreatic β-cells, increased glucose uptake in adipocyte/skeletal muscle, and leading to whole-body improvements in energy homeostasis. Such improvements in metabolic parameters rapidly attracted the attention of biopharmaceutical companies to explore the therapeutic potential of FGF21 in metabolic disorders. Shortly thereafter, however, several disadvantages of utilizing native FGF21 peptide were identified, such as short half-life and biophysical deficiencies (Kharitonenkov & Adams, 2013). In response, numerous analogs and mimetics of FGF21 were developed to overcoming the limitations of the native protein while maintaining the metabolic benefit. Such a new class of molecules includes optimized codon sequence of FGF21 transcript in the pancreas, the adipose tissue, and the skeletal muscle. FGF21 expression is highly regulated by environmental stimuli such as starvation, ketogenic diet, cold exposure, and exercise.

EMBO Mol Med (2018) 10: e9431
See also: Jimenez et al (August 2018)

Our understanding of the physiological role of FGF21 and its pharmacological effects has expanded substantially over the last decade (Degirolamo et al, 2016). FGF21 exerts a multitude of metabolic benefits, including enhanced liver fatty acid oxidation, inhibition of gluconeogenesis, increased adipose thermogenesis, decreased inflammation in pancreatic β-cells, increased glucose uptake in adipocyte/skeletal muscle, and leading to whole-body improvements in energy homeostasis. Such improvements in metabolic parameters rapidly attracted the attention of biopharmaceutical companies to explore the therapeutic potential of FGF21 in metabolic disorders. Shortly thereafter, however, several disadvantages of utilizing native FGF21 peptide were identified, such as short half-life and biophysical deficiencies (Kharitonenkov & Adams, 2013). In response, numerous analogs and mimetics of FGF21 were developed to overcoming the limitations of the native protein while maintaining the metabolic benefit. Such a new class of molecules includes optimized codon sequence of FGF21 transcript in the pancreas, the adipose tissue, and the skeletal muscle. FGF21 expression is highly regulated by environmental stimuli such as starvation, ketogenic diet, cold exposure, and exercise.

EMBO Mol Med (2018) 10: e9431
See also: Jimenez et al (August 2018)

Our understanding of the physiological role of FGF21 and its pharmacological effects has expanded substantially over the last decade (Degirolamo et al, 2016). FGF21 exerts a multitude of metabolic benefits, including enhanced liver fatty acid oxidation, inhibition of gluconeogenesis, increased adipose thermogenesis, decreased inflammation in pancreatic β-cells, increased glucose uptake in adipocyte/skeletal muscle, and leading to whole-body improvements in energy homeostasis. Such improvements in metabolic parameters rapidly attracted the attention of biopharmaceutical companies to explore the therapeutic potential of FGF21 in metabolic disorders. Shortly thereafter, however, several disadvantages of utilizing native FGF21 peptide were identified, such as short half-life and biophysical deficiencies (Kharitonenkov & Adams, 2013). In response, numerous analogs and mimetics of FGF21 were developed to overcoming the limitations of the native protein while maintaining the metabolic benefit. Such a new class of molecules includes optimized codon sequence of FGF21 transcript in the pancreas, the adipose tissue, and the skeletal muscle. FGF21 expression is highly regulated by environmental stimuli such as starvation, ketogenic diet, cold exposure, and exercise.

EMBO Mol Med (2018) 10: e9431
See also: Jimenez et al (August 2018)
gene therapy, resembling many of the metabolic outcomes already reported by using pharmacological FGF21 analogs/mimetics.

While the metabolic benefits of FGF21 treatment have been unquestionable, the underlying mechanisms by which FGF21 improves metabolism have been a matter of debate. For instance, the present study demonstrated increased expression of uncoupling protein 1 (UCP1) and reduction in lipid content in brown adipose tissue (BAT), indicating increased thermogenic activity in the adipose tissue—this is also supported by others (Owen et al., 2014). On the other hand, several studies showed that FGF21 increased whole-body energy expenditure even in mice with ablated interscapular BAT or UCP1 knockout mice, suggesting an UCP1-independent mechanism in response to FGF21 gene therapy. Of note, a recent study showed by using adipocyte-specific β-klotho (Klb) receptor knockout mice that BAT mediates the glucose-lowering effect of FGF21, whereas the anti-obesity effect of FGF21 appears to be through non-adipose tissues (Bon Durant et al., 2017). Thus, future studies are necessary to unveil the molecular and cellular mechanisms by which FGF21 treatment improves metabolic health.

It should be noted that some concerns have been raised regarding the effects related to FGF21 therapy. For example, FGF21 administration can decrease bone mass or promote torpor, a condition where core-body temperature and physical activity are reduced (Khaitonovk & Adams, 2013). However, the AAV-mediated FGF21 gene therapy increased energy expenditure and physical movement with no signs of trabecular or cortical bone loss or changes in bone length. Given the growth factor nature of FGF21 family, the potential tumorigenesis in long-term therapies is also a worthy factor to be addressed. Nonetheless, the present study found that AAV8-hAAT-FGF21 was protected from obesity-associated liver neoplasms, which in turn argues in favor of a protective role of FGF21 against malignancies in the liver. Finally, the authors demonstrated that alternative tissues, such as adipose tissue and skeletal muscle, can be used as host tissues to overexpress FGF21 in cases of liver diseases, including cirrhosis or liver cancer.

In conclusion, Jimenez and colleagues provided a new and efficient way to induce long-term high-circulating FGF21 levels in vivo. The AAV-mediated increase in FGF21 recapitulates most of the previously reported metabolic benefits of pharmacological FGF21 analogs/mimetics while avoiding essential obstacles such as treatment compliance and immunogenic reactions. The present study
opens a new possibility that the AAV-mediated gene therapy can be applied to fight obesity and metabolic diseases.

References
Bon Durant LD, Ameka M, Naber MC, Markan KR, Idiga SO, Acevedo MR, Walsh SA, Ornitz DM, Potthoff MJ (2017) FGF21 regulates metabolism through adipose-dependent and - independent mechanisms. Cell Metab 25: 935–944.e4
Degirolamo C, Sabbà C, Moschetta A (2016) Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 15: 51–69
Emanuelli B, Vienberg SG, Smyth G, Cheng C, Stanford KI, Arumugam M, Michael MD, Adams AC, Kharitonenkov A, Kahn CR (2014) Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest 124: S15–S27
Ikeda K, Kang Q, Yoneshiro T, Camporez JP, Maki H, Homma M, Shinoda K, Chen Y, Lu X, Maretich P et al (2017) UCP1-independent signaling involving SERCA2b-mediated calcium cycling regulates beige fat thermogenesis and systemic glucose homeostasis. Nat Med 23: 1454–1465
Jimenez V, Jambrina C, Casana E, Sacristan V, Muñoz S, Darriba S, Rodó J, Mallo C, García M, León X et al (2018) FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med 10: e8791
Kazak L, Chouchani ET, Jedrychowski MP, Erickson BK, Shinoda K, Cohen P, Vetrivelan R, Lu GZ, Laznik-Bogoslavski D, Hasenfuss SC et al (2015) A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell 163: 643–655
Kharitonenkov A, Adams AC (2013) Inventing new medicines: the FGF21 story. Mol Metab 3: 221–229
Lisowski L, Tay SS, Alexander IE (2015) Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol 24: 59–67
Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, Klewer SA, Mangelsdorf DJ (2014) FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 20: 670–677
Samms RJ, Smith DP, Cheng CC, Antonellis PP, Perfield JW, Kharitonenkov A, Gimeno RE, Adams AC (2015) Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep 11: 991–999

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.